Publish with Us Search
Publish with Us

GenoMed Connect

ISSN: 3105-3645
Volumes

SCIFINITI ALERT!

Subscribe for research updates and exclusive content straight to your inbox

Volume 2

Articles

All Articles
open-access Editorial

Published: 15 Jan 2025

The Potential of Artificial Intelligence and Machine Learning in Pharmacovigilance: An Update

Volume 2

The integration of artificial intelligence (AI) and machine learning (ML) into pharmacovigilance (PV) marks a transformative step towards enhancing drug safety and patient outcomes. With their unparalleled ability to analyze vast and complex datasets, AI/ML technologies offer unprecedented opportunities to revolutionize adverse drug event (ADE) monitoring, signal detection, and causality assessment. This editorial explores the state-of-the-art applications, key challenges, and actionable strategies to unlock the full potential of AI in..

Journal: GenoMed Connect
open-access Research Article

Published: 09 Jan 2025

How Caffeine Affects Alpha-Amylase: An In Vivo Study

Volume 2

Background: Caffeine is a widely consumed psychostimulant with various effects, including weight and metabolic parameters. Caffeine consumption has been associated with increased blood glucose levels and reduced insulin sensitivity. Since xanthine derivatives like caffeine can activate alpha-amylase, an enzyme essential for carbohydrate-to-glucose conversion, this study investigates whether this translates to increased amylase activity in living organisms and explores potential gene expression changes. Methods: Male NMRI mice were divided to 5..

Journal: GenoMed Connect
open-access Research Article

Published: 12 Dec 2024

The Placement of Auer Rods as a Single Diagnostic Criterion for the Highest-Risk Category of Myelodysplastic Syndromes: A Single-Institution Study and Critical Analysis

Volume 2

Accurate determination of prognostic risk is critical for patients and treating clinicians. The French-American-British classification of myelodysplastic syndromes (MDS) described refractory anemia with excess blasts (RAEB) in transformation (RAEB-T), including two subsets with <20% bone marrow (BM) blasts, which were reclassified as RAEB-2, the highest-risk MDS category in the 2001 World Health Organization classification. Those diagnostic criteria have been retained until now with nomenclature changes from RAEB-2 to “MDS with..

Journal: GenoMed Connect
Share
Help